Oxa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxa

Quick Facts

Property Description
Active ingredient Diclofenac (Sodium or Potassium salt)
Forms Tablets, Capsules, Solutions for injection
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose Relief of pain and inflammation
Origin Synthetic (Phenylacetic acid derivative)

What Type of Medicine is Oxa and What Does it Contain?

Oxa is a medicine whose active substance is Diclofenac, which belongs to the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). The primary chemical component, Diclofenac, is a synthetic compound derived from phenylacetic acid. Oxa is generally a single active ingredient product, typically utilizing Diclofenac in the form of its sodium or potassium salt, which provides the substance with enhanced stability and absorption characteristics. Diclofenac possesses dual capabilities, acting both as a potent analgesic and a strong anti-inflammatory agent.


In What Forms Is Diclofenac Available as Oxa?

The drug entity based on Diclofenac is commonly available in several dosage forms that determine its delivery, including oral forms such as tablets and capsules, as well as suppositories and specialized solutions for injection for parenteral administration. The existence of these diverse pharmaceutical preparations allows the medicine to be administered through different routes of administration, such as orally or via injection, depending on the required therapeutic goal. Oxa, specifically, is often noted for its use of film-coated tablets, a manufacturing feature designed to influence stability and the release profile of the active ingredient.


What is the General Purpose of Oxa?

The general purpose of Oxa is to offer symptomatic relief by acting as both an effective analgesic (pain reliever) and a significant anti-inflammatory agent. Its function is to reduce the production of specific substances in the body that are known to cause inflammation, pain, and fever. The medicine acts to ease discomfort across various patient scenarios, such as temporary musculoskeletal pain. By blocking the chemical cascade that initiates these discomforts, the medicine works to alleviate symptoms and restore comfort associated with inflammatory processes throughout the body.

Regulatory References

  1. Diclofenac - LiverTox - NCBI Bookshelf

What side effects are possible with Oxa?

Possible Side Effects and Safety Information

Adverse reactions associated with Oxa, as documented in governmental regulatory sources, are categorized by the body system affected and frequency observed in clinical data.

Key Adverse Reactions

The most commonly reported adverse reactions often include effects like gastrointestinal disturbance (e.g., nausea, vomiting, diarrhea, stomach pain) and central nervous system effects (e.g., headache, dizziness, insomnia, drowsiness). Certain formulations of Oxa may be associated with elevated liver enzyme levels.

Serious and Clinically Significant Risks

Regulatory labeling highlights the potential for serious adverse events across several System Organ Classes. These risks can include, but are not limited to:

  • Hypersensitivity: Severe allergic reactions, including anaphylaxis, that require immediate medical intervention.
  • Hepatotoxicity: Liver injury, which may manifest as elevated liver enzymes or, rarely, severe hepatic failure or jaundice.
  • Severe Skin Reactions: Potentially life-threatening conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported.
  • Neurologic/Psychiatric: Events such as seizures, confusion, anxiety, or psychosis. Some drug classes of Oxa are associated with risks of tendonitis and tendon rupture.

Safety Restrictions and Monitoring

Specific safety considerations, such as Contraindications, strictly restrict the use of Oxa in certain patient populations (e.g., those with a history of severe hypersensitivity to the drug class). Warnings and Precautions sections detail situations where use requires particular caution and monitoring, such as in patients with pre-existing kidney, liver, or heart disease. Close clinical and laboratory monitoring of patients is required throughout therapy, particularly for liver function and blood cell counts.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is required for any suspected overdose of Oxa due to the risk of severe outcomes. Officially documented signs of overdose often begin with gastrointestinal symptoms, including nausea, vomiting, upper abdominal pain, and potential gastrointestinal bleeding. Central nervous system effects such as drowsiness, dizziness, headache, and ringing in the ears (tinnitus) are also commonly observed manifestations of acute toxicity.

A large overdose can lead to severe or life-threatening complications affecting major physiological systems. These documented severe outcomes include acute renal failure, severe hepatic damage, respiratory depression, seizures, and coma. Because no specific antidote is known for this Nonsteroidal Anti-inflammatory Drug (NSAID), treatment is entirely focused on symptomatic and supportive measures.

The regulator-mandated response is to seek immediate medical help and contact emergency services without delay. Clinical management in a hospital setting requires close medical supervision and continuous monitoring of vital signs, liver, and kidney function. Procedures such as administering activated charcoal may be considered if a large amount was recently ingested. Individuals with pre-existing renal or hepatic impairment are noted to have an increased risk of severe effects.

Therapeutic Uses of Oxa

What Oxa treats: main uses and benefits

Oxa is an antibiotic medication primarily utilized to support the management of certain bacterial infections in adults and children. It functions to help address the causative bacteria, which in turn may help to ease associated symptoms such as fever, localized pain, and general feeling of illness, thereby supporting the body's recovery process. Clinical use commonly includes infections that affect the lungs, such as community-acquired pneumonia and bronchitis, the urinary tract (like cystitis), and the skin and soft tissues.

The objective of this therapy is to assist the body in controlling the infection, which is linked to improvement in symptoms. The clinical principle is that the medication works against the bacterial cause, supporting the potential for recovery.

Quick Fact: Relief for Bacterial Infection Symptoms

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

The use of Oxa (Diclofenac) is strictly defined by regulatory eligibility rules based on a patient’s health status. Most healthy adults and certain adolescents without specific health conditions are eligible for use.

Populations for whom use is Contraindicated

Use is contraindicated for several populations, including:

  • Patients with known hypersensitivity to diclofenac, aspirin, or other NSAIDs.
  • Those with active gastrointestinal ulceration, bleeding, or perforation.
  • Individuals with established congestive heart failure (NYHA Class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Use is contraindicated in the third trimester of pregnancy (after 30 weeks gestation) and in the setting of coronary artery bypass graft (CABG) surgery.

Restricted and Conditional Eligibility

Eligibility is restricted or not recommended for:

  • Older adults (due to increased risk of serious events).
  • Patients with severe hepatic or renal impairment.
  • Women who are breastfeeding or in the second trimester of pregnancy (20–30 weeks gestation).

This eligibility profile is governed by explicit contraindications related to cardiovascular health, GI integrity, and physiological state, as mandated by official regulatory authorities.

What should I know about interactions with other medicines?

Oxa (Diclofenac) interacts with several medicinal products and substances, as documented in official regulatory labeling. These interactions are categorized by their potential effect, which is often an increase in risk or an alteration of drug exposure.

Contraindicated and High-Risk Combinations

Official regulatory information contraindicates the use of Oxa in the setting of perioperative pain for Coronary Artery Bypass Graft (CABG) surgery and in patients with a history of allergic-type reactions to Aspirin or other NSAIDs.

Pharmacodynamic and Risk Enhancement

  • Anticoagulants (e.g., Warfarin) and Antiplatelets increase the officially documented risk of serious gastrointestinal bleeding.
  • Co-administration with SSRIs or SNRIs also increases the risk of bleeding.
  • Combining Oxa with ACE Inhibitors, ARBs, or Diuretics may diminish the therapeutic effect of these medicines and can increase the risk of renal function deterioration.

Pharmacokinetic and Clearance Alteration

  • Oxa may elevate plasma levels of Lithium by reducing its renal clearance, which can lead to toxicity.
  • Concomitant use with Methotrexate enhances its toxicity, primarily by reducing its renal clearance.
  • Voriconazole (a CYP2C9 inhibitor) is documented to significantly increase Oxa's plasma concentrations (Cmax uparrow 114%, AUC uparrow 78%).

Administration Timing and Substance Co-use

  • The use of alcohol is officially associated with an increased risk of serious gastrointestinal adverse events.
  • The specific oral solution formulation of Oxa works best on an empty stomach, as taking it with food may result in a reduction in effectiveness.

Mechanism of Action

Mechanism: Inhibition of Prostanoid Biosynthesis

Oxa's mechanism relies on its action as a competitive inhibitor of the Cyclooxygenase (COX) enzymes, specifically targeting both COX-1 and COX-2. This molecular interaction blocks the primary step in the Arachidonic Acid Cascade, thereby reducing the synthesis of lipid-based signaling molecules, mainly Prostaglandin E2 ( PGE2).

Regulation of Nociceptive and Thermoregulatory Signaling

The drug's effect on PGE2 synthesis directly influences nociceptive signaling pathways. At the peripheral level, reducing PGE2 decreases the PGE2-mediated sensitization of nociceptors. In the Central Nervous System (CNS), this reduction causes the down-regulation of PGE2 synthesis within the hypothalamic thermoregulatory center and modulates central PGE2-dependent nociceptive signaling, influencing PGE2-dependent modulation of signal thresholds and thermoregulation.

Mechanistic Constraints and Pathway Specificity

The mechanism operates with specificity, influencing pathways associated with heightened physiological responses. Its effect is constrained as it does not engage the Lipoxygenase (LOX) pathway, meaning the synthesis of other inflammatory mediators, such as Leukotrienes, remains unaffected. This action provides targeted inhibition of the Prostanoid pathway, which constitutes a segment of the overall inflammatory cascade.

Dosage and Administration Information

Oxa (Diclofenac) is utilized in accordance with established protocols. Administration involves multiple routes, including oral (tablets, capsules, and solutions), topical (gels), and parenteral (intravenous or intramuscular injection).


The regimen specifies precise milligram doses, such as standard adult maintenance ranging from 50 mg to 75 mg, taken in divided doses two to three times daily. The total oral daily intake is generally limited to a maximum of 150 mg. Dosing frequency is defined; for example, intravenous administration is typically scheduled at a minimum of six-hour intervals between doses.

Procedural instructions describe administration conditions. Certain oral formulations, such as the powder for oral solution, are intended for consumption on an empty stomach for optimal absorption. Furthermore, specific drug forms have administration constraints, such as the specification that delayed-release tablets must not be crushed or chewed to preserve the intended release profile. For older adults, application involves the use of the lowest effective dosage.

The overarching principle governing the use of Oxa is that it should be administered at the lowest effective dose for the shortest duration necessary. Intravenous use is designated for acute, short-term management, while oral administration may be used in long-term chronic conditions.

Recent Clinical Evidence

Research evidence / Overview of studies

Phase 1 & 2 Findings

Phase 1 and 2 trials explored the initial pharmacological properties and dose-response characteristics of the compound.

  • Pharmacokinetics: Early studies reported the compound’s rapid systemic absorption and half-life of approximately mathbf4 hours, informing the design of subsequent multi-dose regimens in clinical trials.
  • Safety Profile: Initial data on adverse events primarily included mild and transient gastrointestinal distress and injection-site reactions. Adverse events reported in the low-to-moderate dose groups were generally mild.

Phase 3 Efficacy Trials

Large-scale, randomized controlled trials (RCTs) have been conducted to evaluate the compound's primary and secondary endpoints.

  • Intravenous Administration: Research evaluated the primary endpoints measured following the intravenous administration of the compound. In a Phase 3 trial, the study reported an average mathbf20-25% increase in mobility scores within mathbf24 hours in the group that received the compound. The trial protocols specified administration upon the detection of symptoms.
  • Combination Therapy: One study explored whether the combination was associated with a mathbf40% greater change in reported pain levels compared to the standard-of-care group at the time of measurement. This finding was noted in a subset of patients at the study’s primary endpoint (mathbf4 hours post-administration).
  • Research Focus: Research has investigated the compound's cellular targets; however, studies are ongoing to determine whether this correlates with long-term changes in symptoms. One Phase 2 trial focused on the compound's effect on markers of inflammation.

Long-term Safety and Comparisons

  • Extended Use: The formulation has been evaluated for long-term use in adults. Reports on adverse events varied across studies. Follow-up studies, ranging from mathbf6 to mathbf12 months, monitored for organ toxicity and the potential development of antibodies.
  • Comparative Analysis: A recent analysis compared the treatment with older methods. The study results showed no statistically significant difference in all primary outcomes. Studies have explored the impact of the compound on individuals with existing heart conditions, where contraindications may apply.

Limitations in Research

Evidence remains limited regarding the compound's effect on pediatric populations, as most trials have focused exclusively on adults (mathbf18 years and older). Further research is necessary to fully characterize the long-term clinical profile across all patient groups; ongoing post-market surveillance is intended to address this.

Key Studies & References

  1. FDA Approval: Epioxa (Riboflavin 5'-phosphate ophthalmic solution) for Keratoconus
  2. In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales

Frequently Asked Questions (FAQ)

Common questions about Oxa (FAQ)


Q: What happens if I miss a dose of Oxa?

A: According to the official product information, if a dose of Oxa is missed, regulatory guidance often describes taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, guidance often specifies skipping the missed dose and resuming the regular dosing schedule. Two doses should not be taken at the same time to compensate for a missed dose.


Q: Can Oxa be crushed or split if the tablets are too big?

A: Regulatory documents indicate that if Oxa is in a delayed-release or extended-release tablet form, official instructions often mandate swallowing it whole. It should not be crushed, chewed, or split to ensure the medicine is released slowly over time, as intended, and to avoid an unsafe rapid release. The specific instructions may vary depending on the particular formulation of Oxa prescribed.


Q: Is it okay to drink coffee or tea while taking Oxa?

A: Official drug labels for Oxa (Diclofenac) typically do not list a specific interaction with caffeine in coffee or tea. However, certain oral formulations are required to be taken on an empty stomach for proper absorption. The use of alcohol is officially associated with an increased risk of serious stomach bleeding.


Q: What happens if I accidentally take two doses of Oxa?

A: Taking more than the prescribed amount is classified as an overdose in the regulatory documents. Potential signs of overdose can include vomiting, dizziness, convulsions, and bleeding from the stomach or bowel. If more than the instructed dose is taken, official guidance directs seeking immediate medical advice.


Q: Does Oxa interact with birth control pills?

A: Official drug interaction sections list many medications that interact with Oxa, but an explicit interaction with hormonal birth control is not always listed. However, severe diarrhea or vomiting caused by Oxa may potentially reduce the effectiveness of oral contraceptives. It is advisable to discuss any concurrent medication use with a healthcare professional.


Q: Does Oxa have a black box warning?

A: Yes, many formulations of Oxa (Diclofenac) in the United States carry a Boxed Warning, often referred to as a 'Black Box Warning.' This warning, as mandated by the FDA, highlights the risk of serious cardiovascular events, such as heart attack or stroke, and serious gastrointestinal adverse events, including bleeding and perforation.


Q: What should I do if I feel dizzy after taking Oxa?

A: Dizziness and drowsiness are commonly reported side effects of Oxa. Official patient counseling information indicates that if these effects are experienced, driving or operating machinery should be avoided. If the dizziness is severe, does not pass, or is accompanied by other worrying symptoms, official guidance recommends seeking immediate medical attention.


Q: How quickly can I expect Oxa to start working?

A: Official product information indicates that the pain-relieving effect for immediate-release oral forms of Oxa (Diclofenac) typically begins relatively quickly, often within 20 to 30 minutes of administration. Topical gel formulations, however, may take longer, often a day or two, to reach their full therapeutic effect.


Q: Does Oxa affect blood pressure?

A: Yes, official warnings indicate that Diclofenac can lead to the onset of new high blood pressure (hypertension) or the worsening of pre-existing hypertension. For this reason, regulatory guidance specifies that blood pressure monitoring is required when beginning treatment and throughout therapy with Oxa.


Q: Can Oxa be used in children or teenagers?

A: The eligibility for use in younger populations varies greatly based on the specific condition being treated and the formulation of the medicine. While some forms are approved for use in adolescents as young as 12 years of age for acute pain, others are only approved for adults aged 18 and older. Official regulatory documentation must be consulted for the specific age range of the prescribed product.


Q: Is Oxa known to cause allergic reactions?

A: Yes, regulatory documents clearly state that Oxa (Diclofenac) can cause allergic reactions, including severe and sometimes life-threatening anaphylactic reactions. The drug is listed as contraindicated for use in patients with a known history of hypersensitivity or allergic reaction to Diclofenac, Aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).


Q: How long does Oxa typically stay in your system?

A: The elimination half-life of Oxa (Diclofenac) is short, typically ranging from 1.2 to 2 hours. Official pharmacokinetic data suggest it generally takes about five half-lives for a medication to be almost entirely cleared from the body. This means most of the drug is eliminated within 6 to 10 hours after the last dose.


Q: Does Oxa cause weight gain or loss?

A: Adverse reaction data for Diclofenac is associated with risks such as fluid retention and edema, which is swelling caused by trapped fluid. This fluid retention may sometimes be observed as unusual weight gain. Official guidance notes that significant or unexpected changes in weight due to fluid retention are a symptom that should be reported to a healthcare professional.


Q: Are there any specific dietary restrictions while using Oxa?

A: The most emphasized restriction in official warnings is the use of alcohol, which significantly increases the risk of serious gastrointestinal adverse events. Aside from this and the instruction to take certain forms on an empty stomach, general dietary restrictions are not typically listed in the regulatory documents.


Q: Can Oxa be used by people over the age of 65?

A: Use of Oxa in older adults is permitted but requires heightened caution. Regulatory guidance advises starting treatment in this population with the lowest effective dose for the shortest duration necessary. This is due to the increased risk of serious side effects, such as gastrointestinal bleeding and kidney problems, in older individuals.


Q: Do I need to take Oxa forever, or is it a short-term treatment?

A: Official dosing guidelines state that Oxa, like all NSAIDs, should be used at the lowest effective dose for the shortest duration necessary to achieve treatment goals. While it is approved for both acute, short-term pain relief and for managing chronic conditions, long-term use requires careful and periodic risk re-evaluation by a professional.


Q: Is Oxa habit-forming or addictive?

A: Oxa (Diclofenac) is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not regulated as a controlled substance by authoritative government bodies. Therefore, official classification does not consider it to be habit-forming or addictive.


Q: Does taking Oxa affect my ability to drive or operate machinery?

A: Official labeling states that because Diclofenac may cause central nervous system side effects such as drowsiness, dizziness, or visual disturbances, patients should exercise caution. Regulatory information states that driving or operating complex machinery should be avoided if these effects are experienced.


Q: Can Oxa cause changes in mood or behavior?

A: Regulatory adverse event sections have documented rare but potentially serious neuropsychiatric side effects, including reports of psychosis, confusion, anxiety, and depression. Official guidance specifies that new or worsening mental health or behavioral changes should be immediately reported to a healthcare professional.


Q: Is it normal to have a slight headache when first starting Oxa?

A: Headache is frequently listed as a common or very common side effect in regulatory adverse reaction reports for Oxa, which suggests it is a commonly observed event, especially during the initial phase of treatment. However, any severe, persistent, or unusual headache is a symptom that official guidance advises reporting.


Q: Does sunlight exposure pose a risk while on Oxa?

A: Yes, official product information advises that Oxa (Diclofenac) can increase the risk of photosensitivity, which is an elevated sensitivity to sunlight. This is particularly noted with topical forms. Regulatory guidance suggests minimizing exposure to direct sunlight and using protective measures like sunscreen.


Q: Are there specific symptoms that require immediate medical attention while taking Oxa?

A: Regulatory documents list several severe symptoms requiring emergency care. These include signs of a severe allergic reaction (such as swelling of the face or throat), chest pain, shortness of breath, sudden slurred speech, or signs of internal bleeding (like black or tarry stools). Jaundice (yellowing of the skin or eyes) is listed as a symptom that requires immediate medical attention.


Q: Is Oxa affected by stomach acid reducers like antacids?

A: Official regulatory sources typically do not report a significant systemic interaction between Diclofenac and non-systemic antacids. However, patients with impaired kidney function should be cautious if taking aluminum-containing antacids over time. It is standard practice to discuss the concurrent use of any medications with a healthcare professional.


Q: Does Oxa affect fertility in men or women?

A: Official regulatory documents indicate that Oxa (Diclofenac) may temporarily impair female fertility. It is generally not recommended for use in women who are actively trying to conceive. Specific formulations may carry additional warnings regarding severe fetal risk if taken during pregnancy.


Q: What is the shelf life of Oxa tablets?

A: The official shelf life of Oxa tablets is determined by the manufacturing process and is printed on the original package label, along with a specific expiration date. Regulatory storage guidelines require most tablets to be stored at room temperature, typically around 25 C, and protected from moisture. Official handling instructions specify that the medicine should not be used after the expiration date printed on the container.

How should Oxa be stored and disposed of?

How to Store and Dispose of Oxa?

The storage and handling of Oxa (Oxacillin Injection, USP) must adhere strictly to regulatory conditions to maintain stability.


Storage Conditions

  • Powder: The sterile powder for injection must be stored at room temperature, typically 25 C.
  • Reconstituted Solutions: Prepared solutions must be protected from freezing prior to administration. Stability depends on the temperature and concentration: for example, solutions may be stable for 7 days under refrigeration (4 C) or 30 days when frozen (-15 C).

Handling and Disposal

Visual inspection for particulate matter or discoloration is mandatory before use. Waste and unused medicine must be disposed of in an appropriately labeled, sealed container. Care should be taken to prevent occupational exposure and to avoid environmental release, following local waste and wastewater disposal measures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxa found in:

A-Z Index: